Tuesday, May 31, 2016

BRIEF-Daiichi Sankyo provides update on HER3-lung study of patritumab in non-small cell lung cancer

… of patritumab in
non-small cell lung cancer (NCLC)
* Two-Part phase 3 HER3-lung …
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)